Last reviewed · How we verify
Remazolane
Remazolane is a Small molecule drug developed by Second Hospital of Shanxi Medical University. It is currently in Phase 1 development.
Remazolane is a medication being studied in a clinical trial for its effects on elderly adults. The study, titled "A Study on the Correlation Between the Level of Neurofilament Light Chain Protein and the Sensitivity to Remazolane in Elderly Adults," is investigating the correlation between neurofilament light chain levels and remazolane sensitivity in this population.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Remazolane |
|---|---|
| Sponsor | Second Hospital of Shanxi Medical University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Correlation Between Neurofilament Light Chain and Remazolam Sensitivity in Elderly Adults (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remazolane CI brief — competitive landscape report
- Remazolane updates RSS · CI watch RSS
- Second Hospital of Shanxi Medical University portfolio CI
Frequently asked questions about Remazolane
What is Remazolane?
Who makes Remazolane?
What development phase is Remazolane in?
Related
- Manufacturer: Second Hospital of Shanxi Medical University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing